has provided consultation to Acadia Pharmaceuticals, Acumen Pharmaceuticals, ALZpath, Annovis, Aprinoia Therapeutics, Artery Therapeutics, Biogen, Biohaven, BioXcel, Bristol Myers Squibb, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinoxis Therapeutics, Lighthouse Pharmaceuticals, Lilly, Lundbeck, LSP/EQT Life Sciences, Mangrove Therapeutics, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, OptoCeutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, reMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, T-Neuro, TrueBinding and Vaxxinity pharmaceutical, assessment and investment companies
Yes, the IV Glutathione Treatment is completely safe
The reason that we dont, as patients have ownership of our data, is because theres an arbitrage system where this data is bought and sold by various entities outside the patient, and theres a huge market and profitability incentive to keep this data away from patients ownership into the hands of these other entities, whether its the insurer, the PBM, the hospital system, the physician, the pharmacist, whatever it is
Gradual tapering can reduce rapid weight regain, allowing the body to adapt as appetite-regulating effects diminish
